Tagraxofusp in Hematologic Malignancies
Contact
Description
This study involves taking a study drug called Tagraxofusp. Depending on when you join the study, you will either receive tagraxofusp with or without other chemotherapy drugs. The overall goal of this study is to find out if the study drug is safe and effective at treating adults and children with relapsed or refractory CD123+ hematologic malignancies.
Eligibility and criteria
IRB Number:
24-022009
Eligible age range:
Clinical trial phase:
Phase I
Official title:
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.